New Delhi, June 27, 2015: A committee of independent directors formed by Zenotech Laboratories has termed Sun Pharma’s open offer worth Rs 20.23 crore to acquire a little over 28 per cent stake in the company as “fair and reasonable”.
The committee was formed to look into Sun Pharma’s open offer that was necessitated due to its acquisition of Ranbaxy, which held significant stake in Zenotech.
In a filing to the BSE today, Zenotech Laboratories LtdBSE 2.00 % said the independent directors’ panel “believes that the open offer of Rs 20.87 per equity share is fair and reasonable and in line with Sebi regulations”.
Through the open offer, Sun PharmaBSE 0.09 % plans to acquire more than 96 lakh shares of Zenotech, amounting to 28.16 per cent.
The price of Rs 20.87 per share translates to an aggregate of Rs 20.23 crore.
Zenotech shares today closed 1.89 per cent up at Rs 35 apiece on the BSE.
At the end of March, 2015, Sun Pharma and Daiichi Sankyo were the two promoters of Zenotech.
Sun Pharma held 46.85 per cent stake while the shareholding of Daiichi Sankyo stood at 20 per cent, as per latest data available on the BSE.
The Sun Pharma-Ranbaxy merger deal was completed in March this year. In April, 2014, Sun Pharma had announced it would acquire troubled rival RanbaxyBSE 5.63 % in an all-stock transaction worth US$ 4 billion that includes USD 800 million debt.
The merger has created India’s largest and the world’s fifth-largest drugmaker.
